Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Systemic Lupus Erythematosus (BRAVE II)
NCT03616964Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2018
- Primary completion
- Sep 2021
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 15
01
Overview
A Phase 3 trial of baricitinib in systemic lupus erythematosus (SLE), sponsored by Eli Lilly and Company. Started Aug 2018; status: completed.
02
Drugs
baricitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03616964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03616964.